U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177937) titled 'A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of DXC014 for Injection in Patients With Advanced Solid Tumors.' on Sept. 10.
Brief Summary: This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.
Study Start Date: Oct. 20
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer
Melanoma
Prostate Cancer
Other Advanced Solid Tumors
Intervention:
DRUG: DXC014
Dose Escalation DXC014, Cohort Expansion DXC014
Recruitmen...